HospiceCare 2020
Login is Moved!
The Login has been Moved! Look at the very top of the screen - to the right of the ProCare Rx logo!
|
|
HospiceCare 2020 Session Objectives |
|
ProCare HospiceCare 2020
|
2010 Session Objectives
|
|
Presenter: Mary Mihalyo, BS, PharmD
|
|
"Therapeutic Update: Empiric Opioid Utilization, Emerging Dosage Forms of Opioids and the FDA REMS Program"
|
|
Abstract
|
|
|
This session will give you comprehensive information on the opioids most commonly used in end-of-life care. The information will include details on how to choose the most appropriate opioid based on the patient's medical condition, disease process, age, etc. There will be discussion regarding the latest dosage forms and their utility for patients at end-of-life. The session will conclude with an overview and discussion of the REMS (Risk Evaluation and Mitigation Strategy) Program and its possible impact on opioid prescribing.
|
|
Objectives
|
|
-
Identify the most common opioids used in end-of-life care
-
Discuss under what circumstances which opioid should be used
-
List the new dosage forms
-
Determine which new dosage forms will be of value in end-of-life care
-
Analyze the impact of the REMs program on the utilization of opioids in end-of-life care
|
|
Presenter: David Bougher, BSN, RN-BC
|
|
"Comprehensive Management of Nausea & Vomiting"
|
|
Abstract
|
|
|
Next to pain, nausea and vomiting may be the most disturbing symptom a patient can experience at end-of-life. This session will give an overview of the anatomy and physiology of nausea and vomiting and how to comprehensively assess the etiology. There will be discussion regarding what the most effective pharmaceutical interventions may be based on etiology and what role non-pharmaceutical interventions play.
|
|
Objectives
|
|
-
Identify the areas of the brain that play a role in nausea and vomiting
-
List the most common causes of nausea for patients at end-of-life
-
Determine the most effective pharmaceutical interventions based on the etiology of the nausea
-
Discuss the use of non-pharmaceutical interventions in the reduction of the severity of nausea and vomiting
|
|
Presenter: Ted Cuppett, CPA
|
|
“Update on Cost Reporting”
|
|
Abstract
|
|
|
As hospices come under more scrutiny by the regulatory agencies, CMS in particular, cost reporting is not only becoming more complex but increased accuracy is being demanded. An example of this increased scrutiny is CR 6440, which asks hospices to report direct patient care by clinical staff in 15-minute increments. This session will look at these issues and help you strategize how to appropriately develop these reports.
|
|
Objectives
|
|
-
Determine the importance of accurate hospice cost reporting and the value to the hospice and CMS in any hospice payment modifications
-
Identify how to appropriately report more complicated transaction; residential facilities, non-reimbursable activities, transaction with nursing homes and contracted providers
-
Prepare for the changes to the hospice cost report currently under consideration by CMS
|
|
Presenter: Lorin Dutton-Yolch, PharmD
|
|
“The Use of Atypical Antipsychotics in End-of-life Care”
|
|
Abstract
|
|
|
During this session, the latest research regarding atypical antipsychotics and end stage dementia will be discussed. The benefits and burdens of the most commonly used atypical antipsychotics and their cost will be reviewed. You will participate in an analysis of the efficacy of these medications and under what circumstances they are most appropriate.
|
|
Objectives
|
|
-
Identify the most common atypical antipsychotics
-
Discuss the latest research related to the use of atypical antipsychotics in end stage dementia
-
Compare the efficacy of the atypical antipsychotics used in end-of-life care
-
Determine which patients and under what circumstances the atypical antipsychotics are most appropriate
|
|
Presenter: Aletha Tippett, MD
|
|
"Wound Care Management"
|
|
Abstract
|
|
|
In this session, a comprehensive overview of wounds and wound assessment for the patient at end-of-life will be presented. You will participate in discussion of the latest treatment protocols for chronic wound management. You will learn the components of a comprehensive wound assessment and will gain an understanding of the co-morbidities and risk factors that impact patients at end-of-life.
|
|
Objectives
|
|
-
Describe the fundamentals of wound healing
-
Determine the components of a comprehensive wound assessment
-
Identify the main co-morbidities/risk factors related to wounds in patients at end-of-life
-
Describe a palliative treatment protocol for chronic wound management
-
Formulate realistic goals for wound care
-
Devise an appropriate plan of care for wound management
|
|
Presenter: David Bougher, BSN, RN-BC
|
|
"Tales from the Bedside"
|
|
Abstract
|
|
|
Much has been written and stories told about patient and family care givers, but what about us, the hospice professional? This session will focus on stories from and abut the hospice professional. How has the care we've provided met our hospice mission? But just as importantly, how has it met our individual professional mission? Come hear the stories, share your own tales, and learn how acknowledging what we do, makes us healthier hospice professionals.
|
|
Objectives
|
|
-
Identify the components of a story that address the hospice mission/individual professional mission
-
Discuss how the sharing of these stories fosters a healthier professional
-
Discuss what aspects of these stories validate the essence of hospice
|
|
Presenter: Lorin Dutton-Yolch, PharmD
|
|
“The Use of Atypical Antipsychotics in End-of-life Care”
|
|
Abstract
|
|
|
During this session, the latest research regarding atypical antipsychotics and end stage dementia will be discussed. The benefits and burdens of the most commonly used atypical antipsychotics and their cost will be reviewed. You will participate in an analysis of the efficacy of these medications and under what circumstances they are most appropriate.
|
|
Objectives
|
|
-
Identify the most common atypical antipsychotics
-
Discuss the latest research related to the use of atypical antipsychotics in end stage dementia
-
Compare the efficacy of the atypical antipsychotics used in end-of-life care
-
Determine which patients and under what circumstances the atypical antipsychotics are most appropriate
|
|
Presenter: David Bougher, BSN, RN-BC
|
|
"Coping with the New RAC"
|
|
Abstract
|
|
|
As an aspect of providing hospice services under Medicare we have been overseen by the process of medical review as conducted by our Medicare Administrative Contractors (MAC), formerly Fiscal Intermediaries. In 2009 we learned that there will be another review process added by Medicare that will be conducted by a Recovery Audit Contractor (RAC). You will learn what triggers a review, how the review may be conducted and possible implications of that review.
|
|
Objectives
|
|
-
Differentiate between Recovery Audit Contractor and Medicare Administrative Contractor
-
Identify the role of the RACs in the Medicare oversight process
-
Estimate the potential impact RAC oversight may have on hospices
-
Formulate a plan to address a RAC review
|
|
Presenter: Andy Mihalyo, CAHA, MBA
|
|
"Future Competitive Environment for Hospices"
|
|
Abstract
|
|
|
Participants will learn what competition may look like in the future for hospices. Discuss why core competence will be an essential element for positioning in the hospice market. You will learn about strategic architecture and how to use it as a map to the future success of your organization.
|
|
Objectives
|
|
-
Discuss how competition in the future of hospice can be different
-
Explore and explain how core competence can help secure the future
-
Discuss an organization's/company's architecture and how strategic architecture can be a map to the future success of your organization/company
|
|
|
